• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Philips delivers strong margin improvement; flat comparable sales due to further deteriorated demand in China; growth in rest of world

    10/28/24 2:00:00 AM ET
    $PHG
    Medical Electronics
    Health Care
    Get the next $PHG alert in real time by email

    October 28, 2024





    Third-quarter highlights

    • Group sales amounted to EUR 4.4 billion, with flat comparable sales growth
    • Income from operations was EUR 337 million
    • Adjusted EBITA margin increased by 160 basis points from 10.2% to 11.8% of sales
    • Operating cashflow of EUR 192 million, with a free cashflow of EUR 22 million
    • Comparable order intake decreased by 2%, due to decline in China
    • Outlook for full-year 2024 revised to reflect deteriorated demand in China: comparable sales growth within an updated range 0.5%-1.5%, Adjusted EBITA margin at around 11.5%, the upper end of current range; free cashflow at around EUR 0.9 billion, at lower end of current range

    Roy Jakobs, CEO of Royal Philips:

    "In the quarter, demand from hospitals and consumers in China further deteriorated, while we continue to see solid growth in other regions. We have adjusted our full-year sales outlook to reflect the continued impact from China.

    Strong improvement in profitability was driven by progress on our execution priorities, productivity measures and the improved margins of our AI-driven, industry-leading innovations.

    Within a challenging macro environment, we remain focused on successfully executing our three-year plan to fully capture growth and margin expansion opportunities. With patient safety as our number one priority, we are committed to delivering better care for more people."

    Group and segment performance



    Group comparable sales were flat on the back of 11% growth in Q3 2023 and deterioration in demand in China. We delivered growth in all other regions and from an increase in royalty income. China remains a fundamentally attractive growth market for Philips in the long term, with market conditions expected to remain uncertain.

    Adjusted EBITA margin improved 160 basis points from 10.2% to 11.8%, driven by a strong step-up in gross margin from innovations, productivity actions and higher royalty income. Free cash flow was EUR 22 million in the quarter, driven by higher earnings, offset by working capital outflows.

    Comparable order intake in the quarter declined 2% due to China, with solid order intake growth in Diagnosis & Treatment, particularly in the US. Year-to-date comparable order intake grew 1%, including China.

    Diagnosis & Treatment comparable sales decreased 1%, on the back of 14% growth in Q3 2023, with solid growth outside of China. Adjusted EBITA margin was 12.6%.

    Connected Care comparable sales were flat, with growth in Enterprise Informatics and Sleep & Respiratory Care offset by a low- single-digit decline in Monitoring, on the back of high-teens growth in Q3 2023. Adjusted EBITA margin improved from 3.7% to 7.3%.

    Personal Health comparable sales decreased 5% due to a double-digit decline in China, more than offsetting a robust performance elsewhere. Adjusted EBITA margin was 16.5%.



    Productivity

    Our productivity initiatives are on track and delivered savings of EUR 188 million in Q3: operating model savings of EUR 54 million, procurement savings of EUR 58 million, and other programs savings of EUR 76 million. Since 2023, productivity initiatives delivered savings of over EUR 1.5 billion.

    Outlook



    The significant deterioration in China demand leads to an updated comparable sales growth outlook range of 0.5-1.5% for the full year 2024. Comparable sales growth outside of China remains within the 3-5% range. Adjusted EBITA margin is expected to be around 11.5%, the upper end of the range, with free cashflow at around EUR 0.9 billion, at the lower end of the range.

    Within an ongoing challenging macro environment, Philips remains focused on successfully executing its three-year plan to drive operational improvement and create value with sustainable impact. The uncertainties signaled in earlier quarters have intensified in China and are expected to continue.

    The outlook excludes the potential impact of the ongoing Philips Respironics-related legal proceedings, including the investigation by the US Department of Justice.

    Customer, innovation and ESG highlights

    • Philips expanded its next-generation cardiovascular ultrasound platform with FDA clearance of two additional AI algorithms to enhance structural heart disease examinations as part of the global rollout of this technology.
    • Philips secured FDA approval for its new LumiGuide Navigation Wire, which uses fiber optic technology to reduce radiation for both patients and physicians during minimally invasive surgery.
    • Carilion Clinic in the US will expand cardiac care access through 11 specialized Philips interventional suites that allow physicians to treat patients with complex cardiovascular conditions closer to home using platforms including the Azurion Image Guided Therapy System and EPIQ CVx cardiology ultrasound system with AI capabilities.
    • NYU Langone Health in the US successfully implemented Philips' digital pathology solutions as part of an eight-year partnership, enabling patients to be diagnosed faster using real-time digital images instead of microscopes.
    • Siloam Hospital Group, Indonesia's largest private hospital network serving close to 4 million patients a year, is partnering with Philips for digital health and AI transformation. The collaboration aims to improve healthcare access and enhance clinical outcomes, delivering better care for more people in one of the fastest-growing G20 nations.
    • Supporting China in expanding access to care in a new private hospital in Zhangzhou serving half a million patients each year, Philips will be the sole provider of MR, image-guided therapy and ultrasound technologies, enabling high-quality care for patients.
    • Philips launched the AI-powered Avent Premium Connected Baby Monitor, which offers cry translation and SenseIQ technology to track sleep, breathing, and movements, giving parents peace of mind.
    • Philips is collaborating with customers worldwide to help them assess and mitigate their carbon footprints, including Jackson Health System in the US, Rennes University Hospital in France, and Champalimaud Foundation in Portugal.



    Click here to view the release online

    For further information, please contact:





    Elco van Groningen

    Philips External Relations

    Tel.: +31 6 8103 9584

    E-mail: [email protected]



    Ben Zwirs


    Philips External Relations

    Tel.: +31 6 1521 3446

    E-mail: [email protected]



    Dorin Danu

    Philips Investor Relations

    Tel.: +31 20 59 77055

    E-mail: [email protected]





    About Royal Philips

    Royal Philips (NYSE:PHG, AEX: PHIA))) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

    Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

    Forward-looking statements and other important information



    Forward-looking statements



    This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about strategy, estimates of sales growth, future Adjusted EBITA *) , future restructuring and acquisition related charges and other costs, future developments in Philips' organic business and the completion of acquisitions and divestments. Forward-looking statements can be identified generally as those containing words such as "anticipates", "assumes", "believes", "estimates", "expects", "should", "will", "will likely result", "forecast", "outlook", "projects", "may" or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.



    These factors include but are not limited to: Philips' ability to gain leadership in health informatics in response to developments in the health technology industry; Philips' ability to keep pace with the changing health technology environment; macro-economic and geopolitical changes; integration of acquisitions and their delivery on business plans and value creation expectations; securing and maintaining Philips' intellectual property rights, and unauthorized use of third-party intellectual property rights; Philips' ability to meet expectations with respect to ESG-related matters; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; breaches of cybersecurity; challenges in simplifying our organization and our ways of working; the resilience of our supply chain; attracting and retaining personnel; challenges in driving operational excellence and speed in bringing innovations to market; compliance with regulations and standards including quality, product safety and (cyber) security; compliance with business conduct rules and regulations including privacy and upcoming ESG disclosure and due diligence requirements; treasury and financing risks; tax risks; reliability of internal controls, financial reporting and management process; and global inflation. As a result, Philips' actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Risk management chapter included in the Annual Report 2023. Reference is also made to section Risk management in the Philips semi-annual report 2024.



    Third-party market share data



    Statements regarding market share contained in this document, including those regarding Philips' competitive position, are based on outside sources such as specialized research institutes, as well as industry and dealer panels, in combination with management estimates. Where information is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management's estimates of rankings are based on order intake or sales, depending on the business.



    Market Abuse Regulation



    This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.



    Use of non-IFRS information



    In presenting and discussing the Philips Group's financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2023.



    Presentation



    All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2023. Prior-period amounts have been reclassified to conform to the current-period presentation; this includes immaterial organizational changes.



    Effective Q1 2024, Philips has revised the order intake policy to reflect the full contract value for software contracts that start generating revenue within an 18-month horizon, instead of only the next 18-months-to-revenue horizon. This change has been implemented to better align with the specific business model of our software businesses, simplify the order intake process, and better align with peers. Prior-period comparable order intake percentages have been restated accordingly. This revision has not resulted in any material changes to the order intake percentages for the periods presented.



    Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares in the second quarter of 2024 in connection with the 2023 share dividend.



    *) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.



    Primary Logo

    Get the next $PHG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What were the total group sales for Philips in the third quarter of 2024 and what was the reason for the sales growth slowdown?

      Philips reported group sales of EUR 4.4 billion for Q3 2024, with flat comparable sales growth mainly due to a decline in demand in China.

    • How much did the adjusted EBITA margin improve for Philips in Q3 2024 and what were the main factors contributing to this improvement?

      The adjusted EBITA margin improved by 160 basis points from 10.2% to 11.8% of sales due to enhanced gross margins from innovations and productivity actions.

    • What is the revised outlook for Philips' comparable sales growth and adjusted EBITA margin for the full year 2024?

      Philips revised its full-year 2024 outlook, expecting comparable sales growth in the range of 0.5%-1.5% and adjusted EBITA margin around 11.5%.

    • What impact has the demand from China had on Philips' sales performance in Q3 2024?

      Demand from hospitals and consumers in China has deteriorated, which affected the overall sales performance; however, growth was still observed in other regions.

    • What new product did Philips launch that incorporates AI technology during Q3 2024?

      Philips launched the AI-powered Avent Premium Connected Baby Monitor, enhancing its innovation portfolio while focusing on AI-driven healthcare solutions.

    Recent Analyst Ratings for
    $PHG

    DatePrice TargetRatingAnalyst
    2/25/2025Neutral → Outperform
    Exane BNP Paribas
    2/20/2025Neutral → Buy
    UBS
    10/29/2024Underperform → Hold
    Jefferies
    5/13/2024Mkt Perform → Outperform
    Bernstein
    5/7/2024Underperform → Neutral
    Exane BNP Paribas
    4/30/2024Sell → Neutral
    UBS
    4/30/2024Underweight → Neutral
    JP Morgan
    2/7/2024Outperform → Underperform
    Exane BNP Paribas
    More analyst ratings

    $PHG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Philips upgraded by Exane BNP Paribas

      Exane BNP Paribas upgraded Philips from Neutral to Outperform

      2/25/25 7:12:36 AM ET
      $PHG
      Medical Electronics
      Health Care
    • Philips upgraded by UBS

      UBS upgraded Philips from Neutral to Buy

      2/20/25 7:05:01 AM ET
      $PHG
      Medical Electronics
      Health Care
    • Philips upgraded by Jefferies

      Jefferies upgraded Philips from Underperform to Hold

      10/29/24 6:28:08 AM ET
      $PHG
      Medical Electronics
      Health Care

    $PHG
    Leadership Updates

    Live Leadership Updates

    See more

    $PHG
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PHG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $PHG
    Financials

    Live finance-specific insights

    See more

    $PHG
    SEC Filings

    See more
    • Philips shareholders approve all proposals at the AGM 2025

      May 8, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2025, including: The re-appointment of Ms Indra Nooyi and Ms Chua Sock Koong as members of the Supervisory Board.The appointment of Mr Bob White as a new member of the Supervisory Board.The re-appointment of Mr Marnix van Ginneken as member of the Board of Management. The discharge of the members of the Board of Management, and of the members of the Supervisory Board.A full overview of the resolutions taken at the AGM 2025 can be found below. Feike Sijbesma, Chairman of Philips' Supervisory Board, sa

      5/8/25 12:16:51 PM ET
      $PHG
      Medical Electronics
      Health Care
    • Philips proposes new Supervisory Board appointments and reappointments, and Board of Management reappointment

      Mr David Pyott to retire from Philips' Supervisory Board after his third consecutive term.Mr Bob White proposed as new member of the Supervisory Board.Ms Indra Nooyi and Ms Chua Sock Koong proposed for reappointment as members of the Supervisory Board.Mr Marnix van Ginneken proposed for reappointment as member of Philips' Board of Management. February 19, 2025Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced proposed Supervisory Board appointments and reappointments, and a proposed Board of Management reappointment. Mr David Pyott (British/American, 1953) will retire from Philips' Supervisory Board at the end of the Annu

      2/19/25 1:05:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • Philips appoints Jie Xue as Chief Business Leader Precision Diagnosis, co-leader of the Diagnosis & Treatment segment, and Özlem Fidanci as Chief of International Region

      January 9, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the appointment of Jie Xue as Chief Business Leader Precision Diagnosis, and Özlem Fidanci as Chief of International Region, both effective January 1, 2025. Ms. Xue and Ms. Fidanci have joined Philips' Executive Committee and report directly to Roy Jakobs, CEO of Philips.Ms. Xue joins Philips from GE Healthcare to lead the Precision Diagnosis business that was temporarily led by Bert van Meurs, who will continue to lead Philips' Image Guided Therapy business. Ms. Xue and Mr. Van Meurs will be jointly responsible for the Diagnosis & Treatment segment. Ms. F

      1/9/25 4:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • Philips shareholders approve all proposals at the AGM 2025

      May 8, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2025, including: The re-appointment of Ms Indra Nooyi and Ms Chua Sock Koong as members of the Supervisory Board.The appointment of Mr Bob White as a new member of the Supervisory Board.The re-appointment of Mr Marnix van Ginneken as member of the Board of Management. The discharge of the members of the Board of Management, and of the members of the Supervisory Board.A full overview of the resolutions taken at the AGM 2025 can be found below. Feike Sijbesma, Chairman of Philips' Supervisory Board, sa

      5/8/25 12:16:51 PM ET
      $PHG
      Medical Electronics
      Health Care
    • Philips delivers on Q1 results, with ongoing order intake growth

      May 6, 2025Q1 2025 Group performance Group sales EUR 4.1 billion, reflecting a 2% decline in comparable sales growth mainly due to China; slightly ahead of company outlook due to Personal Health growth and royalty phasingComparable order intake increased 2% despite China declineIncome from operations increased to EUR 154 millionAdjusted EBITA margin declined 80 bps to 8.6% of sales, driven by sales phasingFree cash outflow of EUR 1,091 million included EUR 1,025 million payment for Philips Respironics recall-related medical monitoring and personal injury settlements in USUpdated full year 2025 outlook for Adjusted EBITA margin and free cash flow; sales outlook remains unchanged Roy Jakobs,

      5/6/25 1:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • New Philips Norelco Shaver i9000 Prestige Ultra Introduces the Brand's First "Root-Level" Shave, for Closest Shave Yet

      The World's Most intelligent Shaver from Philips Norelco sets new standards for closeness, comfort and customization. CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, is introducing the newest addition to its signature rotary shaving product suite with its most groundbreaking shaver yet. Philips Norelco Shaver i9000 Prestige Ultra, powered by artificial intelligence (AI), is the most intelligent shaver on the market, delivering on maximum comfort, superior precision, and ultimate personalization while providing a seamless user experience and results that last all day.

      5/1/25 9:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Koninklijke Philips N.V. NY Registry Shares

      SC 13D/A - KONINKLIJKE PHILIPS NV (0000313216) (Subject)

      6/25/24 4:35:57 PM ET
      $PHG
      Medical Electronics
      Health Care
    • SEC Form SC 13D/A filed by Koninklijke Philips N.V. NY Registry Shares (Amendment)

      SC 13D/A - KONINKLIJKE PHILIPS NV (0000313216) (Subject)

      5/16/24 5:52:57 PM ET
      $PHG
      Medical Electronics
      Health Care
    • SEC Form SC 13D filed by Koninklijke Philips N.V. NY Registry Shares

      SC 13D - KONINKLIJKE PHILIPS NV (0000313216) (Subject)

      8/23/23 12:44:28 PM ET
      $PHG
      Medical Electronics
      Health Care
    • Philips delivers on Q1 results, with ongoing order intake growth

      May 6, 2025Q1 2025 Group performance Group sales EUR 4.1 billion, reflecting a 2% decline in comparable sales growth mainly due to China; slightly ahead of company outlook due to Personal Health growth and royalty phasingComparable order intake increased 2% despite China declineIncome from operations increased to EUR 154 millionAdjusted EBITA margin declined 80 bps to 8.6% of sales, driven by sales phasingFree cash outflow of EUR 1,091 million included EUR 1,025 million payment for Philips Respironics recall-related medical monitoring and personal injury settlements in USUpdated full year 2025 outlook for Adjusted EBITA margin and free cash flow; sales outlook remains unchanged Roy Jakobs,

      5/6/25 1:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • Philips convenes the Annual General Meeting of Shareholders 2025

      March 24, 2025Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)) today announced it has convened the Annual General Meeting of Shareholders (AGM) 2025 and published the agenda with explanatory notes.As previously announced, the agenda includes: Proposal to appoint Mr Bob White (American, 1962) as a new member of the Supervisory Board, with effect from May 8, 2025.Proposals to re-appoint Ms Indra Nooyi (American, 1955) and Ms Chua Sock Koong (Singaporean, 1957) as members of the Supervisory Board, with effect from May 8, 2025.Proposal to re-appoint Mr Marnix van Ginneken (Dutch, 1973) as a member of the Philips Board of Management, with effect from May 8, 2025.  The agenda fu

      3/24/25 4:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • Philips delivers growth, improved profitability, and strong cash flow in Q4 and 2024; continues solid execution of its three-year plan

      February 19, 2025Full Year and Q4 Group performance highlights Sales of EUR 18.0 billion in 2024, comparable sales growth 1%; EUR 5.0 billion in Q4, comparable sales growth 1%, despite double-digit decline in ChinaComparable order intake increased 1% in 2024; up 2% in Q4, despite double-digit decline in ChinaIncome from operations was EUR 529 million in 2024; EUR 199 million in Q4Adjusted EBITA margin increased 90 basis points to 11.5% of sales in 2024; up 60 basis points to 13.5% in Q4Net cash flow from operating activities was EUR 1,569 million in 2024; EUR 1,459 million in Q4Free cash flow was EUR 906 million in 2024; EUR 1,285 million in Q4Finalized Philips Respironics recall-related me

      2/19/25 1:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by Koninklijke Philips N.V. NY Registry Shares

      6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)

      5/6/25 7:58:01 AM ET
      $PHG
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by Koninklijke Philips N.V. NY Registry Shares

      6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)

      3/24/25 8:18:19 AM ET
      $PHG
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by Koninklijke Philips N.V. NY Registry Shares

      6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)

      2/21/25 10:15:15 AM ET
      $PHG
      Medical Electronics
      Health Care